Panebianco Martina, Ciccarese Chiara, Strusi Alessandro, Beccia Viria, Carbone Carmine, Agostini Antonio, Piro Geny, Tortora Giampaolo, Iacovelli Roberto
Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Medical Oncology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Cancers (Basel). 2024 Jan 23;16(3):490. doi: 10.3390/cancers16030490.
In recent years, the first-line available therapeutic options for metastatic renal cell carcinoma (mRCC) have radically changed with the introduction into clinical practice of new immune checkpoint inhibitor (ICI)-based combinations. Many efforts are focusing on identifying novel prognostic and predictive markers in this setting. The complement system (CS) plays a central role in promoting the growth and progression of mRCC. In particular, mRCC has been defined as an "aggressive complement tumor", which encompasses a group of malignancies with poor prognosie and highly expressed complement components. Several preclinical and retrospective studies have demonstrated the negative prognostic role of the complement in mRCC; however, there is little evidence on its possible role as a predictor of the response to ICIs. The purpose of this review is to explore more deeply the physio-pathological role of the complement in the development of RCC and its possible future use in clinical practice as a prognostic and predictive factor.
近年来，随着基于新型免疫检查点抑制剂（ICI）的联合疗法引入临床实践，转移性肾细胞癌（mRCC）的一线可用治疗选择发生了根本性变化。许多研究工作都集中在确定这一背景下的新型预后和预测标志物。补体系统（CS）在促进mRCC的生长和进展中起着核心作用。特别是，mRCC被定义为一种“侵袭性补体肿瘤”，它包括一组预后不良且补体成分高度表达的恶性肿瘤。多项临床前和回顾性研究已证明补体在mRCC中的负面预后作用；然而，关于其作为ICI反应预测指标的潜在作用，证据很少。本综述的目的是更深入地探讨补体在RCC发生发展中的生理病理作用及其未来在临床实践中作为预后和预测因素的可能用途。
